These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
45. Sinemet in Parkinson's disease: efficacy with and without food. Bozek CB; Suchowersky O; Purves S; Calne S; Calne DB Clin Neuropharmacol; 1986; 9(2):196-9. PubMed ID: 3708604 [No Abstract] [Full Text] [Related]
46. Treatment of chronic Parkinson's disease with controlled-release carbidopa/levodopa. Hutton JT; Morris JL; Román GC; Imke SC; Elias JW Arch Neurol; 1988 Aug; 45(8):861-4. PubMed ID: 3395259 [TBL] [Abstract][Full Text] [Related]
47. [Effectiveness of slow release L-DOPA/benserazide in treatment of end-of-dose akinesia in Parkinson disease]. Eichhorn TE; Schrag A; Trenkwalder C; Selzer R; Kohnen R; Oertel WH; Poewe W Nervenarzt; 1995 Dec; 66(12):933-41. PubMed ID: 8584079 [TBL] [Abstract][Full Text] [Related]
48. Effect of the putative dopamine D1 agonist and D2 antagonist FCE 23884 on Parkinson's disease. Metman LV; Blanchet PJ; de Jong D; Mouradian MM; Chase TN Mov Disord; 1996 May; 11(3):257-60. PubMed ID: 8723141 [TBL] [Abstract][Full Text] [Related]
49. Treatment of Parkinson's disease. From theory to practice. Ahlskog JE Postgrad Med; 1994 Apr; 95(5):52-4, 57-8, 61-4 passim. PubMed ID: 8153048 [TBL] [Abstract][Full Text] [Related]
50. Comparison of standard carbidopa-levodopa and sustained-release carbidopa-levodopa in Parkinson's disease: pharmacokinetic and quality-of-life measures. Pahwa R; Lyons K; McGuire D; Silverstein P; Zwiebel F; Robischon M; Koller WC Mov Disord; 1997 Sep; 12(5):677-81. PubMed ID: 9380047 [TBL] [Abstract][Full Text] [Related]
51. Fluctuations in plasma levodopa and motor responses with liquid and tablet levodopa/carbidopa. Metman LV; Hoff J; Mouradian MM; Chase TN Mov Disord; 1994 Jul; 9(4):463-5. PubMed ID: 7969216 [TBL] [Abstract][Full Text] [Related]
52. Objective evidence for tolerance, against a background of improvement, during maintenance therapy with controlled release levodopa/carbidopa. Bowes SG; Dobbs RJ; Henley M; Charlett A; O'Neill CJ; Nicholson PW; Purkiss AG; Weller C; Dobbs SM Eur J Clin Pharmacol; 1992; 43(5):483-9. PubMed ID: 1483485 [TBL] [Abstract][Full Text] [Related]
53. Standard and controlled-release levodopa/carbidopa in patients with fluctuating Parkinson's disease on a protein redistribution diet. A preliminary report. Karstaedt PJ; Pincus JH; Coughlin SS Arch Neurol; 1991 Apr; 48(4):402-5. PubMed ID: 2012514 [TBL] [Abstract][Full Text] [Related]
54. Long-term evaluation of Sinemet CR in parkinsonian patients with motor fluctuations. Hutton JT; Morris JL Can J Neurol Sci; 1991 Nov; 18(4):467-71. PubMed ID: 1782612 [TBL] [Abstract][Full Text] [Related]
55. Controlled release levodopa/carbidopa (Sinemet CR4) in Parkinson's disease--an open evaluation of efficacy and safety. Bulling MT; Wing LM; Burns RJ Aust N Z J Med; 1991 Aug; 21(4):397-400. PubMed ID: 1953526 [TBL] [Abstract][Full Text] [Related]
56. Nasogastric and intravenous infusions of (+)-4-propyl-9-hydroxynaphthoxazine (PHNO) in Parkinson's disease. Coleman RJ; Quinn NP; Traub M; Marsden CD J Neurol Neurosurg Psychiatry; 1990 Feb; 53(2):102-5. PubMed ID: 1968963 [TBL] [Abstract][Full Text] [Related]
58. Sinemet (CR4): an open-label study in moderately severe Parkinson's disease. Ming A; Temlett JA; Fritz VU J Intern Med; 1991 Aug; 230(2):113-7. PubMed ID: 1865161 [TBL] [Abstract][Full Text] [Related]
59. The efficacy of (+)-4-propyl-9-hydroxynaphthoxazine as adjunctive therapy in Parkinson's disease. Weiner WJ; Factor SA; Sanchez-Ramos JR J Neurol Neurosurg Psychiatry; 1989 Jun; 52(6):732-5. PubMed ID: 2746265 [TBL] [Abstract][Full Text] [Related]
60. The long-duration action of levodopa may be due to a postsynaptic effect. Barbato L; Stocchi F; Monge A; Vacca L; Ruggieri S; Nordera G; Marsden CD Clin Neuropharmacol; 1997 Oct; 20(5):394-401. PubMed ID: 9331515 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]